Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for DARBEPOETIN ALFA
- Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers
- The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy
- Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants
- Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease
- Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
- Erythropoietin and Darbepoetin in Neonatal Encephalopathy Trial
- The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp
- Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
- A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.
- Desidustat in the Treatment of Anemia in CKD
- Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease
- Ferric Carboximaltose on Intra-myocardial Iron Load in Patients With Heart Failure
- Mechanisms of EPO-induced Hypertension
- Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.
- Maintenance Treatment of Renal Anemia in Dialysis Subjects
- Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)
- Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)
- Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan
- Erythropoietin Role in Acute Kidney Injury
- A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects
- A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects
- Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
- Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial
- Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration
- Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants
- EPO-4-Rhesus Study
- Mild Encephalopathy in the Newborn Treated With Darbepoetin
- Ferric Citrate in ESRD Pilot Project
- A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
- A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)
- A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia
- A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
- Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
- Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
- Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients
- Erythropoietin and Iron Supplementation for Patients With Chemotherapy-induced Anaemia
- Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
- Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
- Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers
- Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients
- Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
- Darbepoetin Alfa MDS Companion Protocol
- Long-term Pre-dialysis Extension in Europe and Asia Pacific
- Comparison Among Erythropoietin Stimulating Agents
- Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934
- Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa
- A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug
- Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4
- ESAs, Reticulocyte Dynamic and Hemoglobin Variability
- 4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
- PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease
- Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct Remodeling
- Darbe Administration in Newborns Undergoing Cooling for Encephalopathy
- Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease
- Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
- Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)
- Effect of Darbepoetin in Contrast-induced Nephropathy
- Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes
- Intracoronary Injection of Epo After Myocardial Infarct "Intra-CO-EpoMI"
- Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.
- Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease
- A Proof-of-Concept Study of Darbepoetin Alfa in Partial Correction of Anemia in Chinese With Diabetic Nephropathy
- Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease
- A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia
- Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
- Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.
- A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.
- Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis
- A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia
- Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
- A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis
- The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial
- A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis
- A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.
- A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.
- Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
- Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
- Study of Erythropoietin to Treat Anemia Complicating Chronic Obstructive Pulmonary Disease
- Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia
- A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis
- Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)
- Anaemia Correction in Haemodialyzed Patients - Comparative Analysis of Two Erythropoietin Stimulating Agents Schedules
- A Study of Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia
- MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Participants With Chronic Renal Anemia
- Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)
- Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa
- An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial
- Phase 2 Study of Darbepoetin Alfa Extended Dosing
- Fixed Dose NESP Study in Subjects With CRI
- Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal Anemia
- MAGIC Cell-5-Combicytokine Trial
- A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.
- A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.
- Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)
- A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.
- Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis
- Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
- Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
- A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
- Darbepoetin Alfa With or Without Intravenous (IV) Iron
- Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes
- A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients
- A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
- Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients
- Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer
- COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
- Safety of Darbepoetin Alfa Treatment in Patients With Severe Traumatic Brain Injury
- STAAR-1 Clinical Study
- STAAR-3 Clinical Study
- STAAR-2 Clinical Study
- STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients
- A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor
- RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
- Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation
- Darbepoetin Administration to Preterm Infants
- A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
- Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia
- Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer
- Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide
- Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia
- Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia
- ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer
- Study of Aranesp to Treat Anemia in Prostate Cancer Patients.
- Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies
- Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)
- A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)
- Darbepoetin Treatment of Anemia in Children With Chronic Renal Failure
- Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced
- Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)
- A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer
- Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.
- Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer
- R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma
- Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy
- AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies
- An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)
- The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery
- Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease
- Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy
- Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy
- Treatment for Patients Suffering From Anemia Due to Chemotherapy
- Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy
- A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa
- Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects
- A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
- A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy
- A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects
- Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia
- Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis
- A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study
- Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis
- Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis
- Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy
- Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy
- Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis
- Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
- Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis
- Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer
- A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome
- Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease
- Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)
- Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
- Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia
- A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
- Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
- Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
- Heart Failure and Anemia
- Anemia in Patients With a Non-Myeloid Malignancy
- Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies
- Chemotherapy Related Anemia
Clinical trials list
click for details